ASCO, Clinical Trials for Life
A look at the clinical trials side of oncology.
As I write this, it is three days before the ASCO Annual Meeting, the first in a series of conferences that arrive in rapid succession, such as CMSC, ASMS, ACR, and the many more conferences that the healthcare brands under MJH Life Sciences® cover. For the Applied Clinical Trials’ audience, we also look forward to attending the Drug Information Association (DIA) Global Annual Meeting at the end of June in Boston.
However, it is ASCO that holds a special place at the heart of MJH. Our flagship iconic oncology brands include OncLive®, Targeted Oncology™, CancerNetwork®, and CURE®. We also offer academic and community oncologists, nurses, patients, and all involved with the cancer care journey with an unmatched selection of resources. These include our live educational events, along with digital and print solutions that deliver the peer-to-peer education needed for improving patient outcomes. From video editorials to conference coverage, we independently produce content that combines objective facts and expert insights for the cancer care community.
While Applied Clinical Trials’ mission isn’t to report the clinical trial results, it is the results from the actual conduct of these oncology clinical trials that are reported. Where would oncology trials be without a team of investigators, clinical research coordinators, data managers, lab providers, medical writers, and many more? That is where Applied Clinical Trials comes in, on the operations side of drug development.
Clinical trials represent the research side of the clinical care continuum in oncology. Of all the therapies in development, oncology is the largest in the pipeline. That is representative of the true need for cancer treatments. While many patients can participate in clinical trials, many more do not or are not given access due to lack of knowledge or overly strict exclusion criteria.
On both sides of our business—healthcare and industry sciences—we continuously hear about those who have entered the field of oncology in a variety of roles to make an impact on those suffering from cancer. Whether it is an investigator, a pharma CEO, CRO project manager, or clinical research nurse, many are on the front lines with their stories that touch a tremendous amount of people with their compassion. We would like to thank them all for bringing us one step closer to a world without cancer.
Thank you for reading.
Mike Hennessy Jr., president and CEO, MJH Life Sciences®
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
